| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Michael Lefenfeld last filed a Form 4 in June 2023, as Director at IMNM. Michael Lefenfeld's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Michael Lefenfeld's trades have earned a below-average insider score of 13/100 across 3 rated trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -83.0%.
At the last filing, the largest reported position was 40,747 shares of IMNM. Net of sales, the IMNM filings show accumulation of 4,650 shares.
Michael Lefenfeld has 7 Form 4 filings on record from October 2020 to June 2023, all as Director at Immunome (IMNM), 2020–2023.
The 9 reported transactions were 4 option or other derivative awards, 3 open-market purchases, 1 stock award and 1 conversion.
Counted by filing, the open-market trades come to 1 purchase worth about $86K and no sales.
The only open-market purchase was 4,650 shares of IMNM at an average $18.53 on May 26, 2021, about $86K. Twelve months later IMNM was down 83%.
Shares as reported in the last Form 4 for each company; the most recent is from June 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 26, 2021 | IMNM Immunome Inc. | Director | Buy | 4,650 | $18.53 | $86,149.65 | +20.9% | -29.8% | -83.4% |